Fresenius Kabi

Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies. Our products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s primary focus is on meeting the needs of patients and health care professionals while acting responsibly to our people, society, and environment.

Highlights 2020

Maximizing production capacity of key products during COVID-19 pandemic

Fresenius Kabi has responded to the significant increase in worldwide demand for essential drugs and infusion technology for the treatment of COVID-19 patients, especially medicines for sedation such as Propofol, pain management drugs, and infusion pumps. We maximized supply, with all compatible manu­facturing capacity dedicated to these important products.

Commitment to keep prices stable

We have committed ourselves to keep prices for essential drugs for COVID-19 patients stable during this pandemic.

Accelerated internationalization of our product portfolio

We continued to expand our global presence, achieving double-digit growth in our enteral nutrition business in northeast and southeast Asia and in Latin America. Another important milestone is the market coverage of our 3-chamber bags, with which we are now present in more than 100 countries worldwide.

Further progress in our biosimilars BiosimilarsA biosimilar is a drug that is “similar” to another biologic drug already approved. business

We received acceptance for review of the regulatory submission from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDAFDA (U.S. Food & Drug Administration)Official authority for food observation and drug registration in the United States.) for our pegfilgrastim biosimilar candidate. These are important milestones following last year’s approval and launch of our first biosimilar product Idacio (adalimumab) in Europe.

Comprehensive product portfolio

IV drugs

Intravenously administered generic drugs (IV) across a wide array of therapeutic categories: oncology, anesthetics, analgesics, anti-infectives, and critical care. This type of administration is used in cases of emergency, since the drug reaches the entire human body directly through the bloodstream and can be effective within a few seconds. IV drugs are also administered in intensive care and during surgery.

Clinical nutrition

Parenteral nutrition (administered intravenously) and enteral nutrition (administered as sip or tube feed via the gastro­intestinal tract). Both serve to help patients who cannot eat any, or sufficient, normal food.

Infusion therapy

Infusion solutions and blood volume substitutes.

Biosimilars

Focus on autoimmune diseases and oncology. A biosimilar is a biological medicine highly similar to another already-approved biological medicine (the “reference medicine”).

Medical devices

Devices and disposables used to administer IV generic drugs, infusion therapies, and clinical nutrition products.

Transfusion technology

Products for collection of blood components and extra­corporeal therapies.

Our success factors

  • Improve the quality of life of our patients
  • Affordable high-quality products
  • Supply reliability
  • Highly qualified employees
  • Strong global footprint
  • Leading market positions
  • Innovation in products, processes, and systems

Our growth drivers

  • Organic growth through geographic product rollouts and product launches
  • Development of qualified and talented employees
  • Strong product pipeline
  • Development and rollout of biosimilars
  • Increasing presence in emerging markets
  • Selective small and mid-sized acquisitions

Market dynamics

Continuing growth of generics and biopharmaceuticals in 2021 expected

5 – 7%

for generic IV drugs (in sales/€)

5 - 7%

for biopharmaceuticals (in volume)

Growing health care spending in emerging markets

+ 6.3%

growth p.a. over the next decade

Global addressable market 2020

~ € 105 bn

Rising cost consciousness in health care spending – significant savings from generics

~ US$ 293 bn

savings p.a. in the United States

~ € 100 bn

savings p.a in the EU

Increase in the aging population to

16%

of total population will be > age 65 by 2050 (9% in 2019)

Sales and earnings development

Download (XLSX, 35 KB)
Europe
in € millions 2020 2019 Change Change in constant currency
Sales 2,458 2,313 +6% +7%
EBIT 355 329 +8% +9%
Employees 15,124 14,812 +2%
Download (XLSX, 35 KB)
North America
in € millions 2020 2019 Change Change in constant currency
Sales 2,376 2,424 -2% 0%
EBIT 785 909 -14% -12%
Employees 8,809 8,321 +6%
Download (XLSX, 35 KB)
Emerging markets
in € millions 2020 2019 Change Change in constant currency
Sales 2,142 2,182 -2% +6%
EBIT 471 478 -1% +5%
Employees 16,586 16,494 +1%

Source:
Continuing growth of generics and biopharmaceuticals in 2021 expected
Source: own research Fresenius Kabi

Global addressable market 2020 ~ € 105 bn
Source: own research Fresenius Kabi

Increase in the proportion of the population over 65 years of age
Source: https://www.un.org/en/sections/issues-depth/ageing/

Growing health care spending in emerging markets
Source: UBS, Longer Term Investments: EM healthcare (2018)

Rising cost consciousness in health care spending – significant savings from generics
Source: Association for Accessible Medicines (AAM): 2019 Generic Drug and Biosimilars Access and Savings
in the U.S.; IMS Health 2015, The Role of Generic Medicines in Sustaining Healthcare Systems – A European Perspective

Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-2294
pr-fre@fresenius.com

Visit us

Fresenius SE & Co. KGaA

Fresenius Medical Care

Fresenius Helios